Imunon Reports Q3 2026 Net Loss of $3.8 Million and Advances IMNN-001

Imunon reported a Q3 2026 net loss of $3.8M, or $0.64 per share, compared to $3.4M, or $1.16 per share, a year earlier. Operating expenses were $3.4M. The company updated its Phase 3 ovarian cancer study and other programs, with enrollment expected to complete by Q1 2029. Imunon also transferred ThermoDox rights to VoxelDox, contingent on funding.

Original reporting
Published Nov 12, 2026, 1:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 1:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Imunon Reports Q3 2026 Net Loss of $3.8 Million and Advances IMNN-001 — source image
Decision brief

The 30-second read

$IMNNBearishMed
01

Why it matters

The earnings miss and cash burn suggest short‑term downside, but the advancement of a Phase 3 trial and a strategic rights transfer to VoxelDox could be catalysts for future upside.

02

Market read

The filing provides fresh financial and clinical trial data that can move Imunon's stock in after‑hours trading and informs biotech sector sentiment.

03

What to watch

Potential partnership with VoxelDox and equity stake may provide future revenue streams not reflected in the loss.

Relevance 7/10Novelty 7/10Timing: post‑market today

Background

Imunon Inc. (IMNN) released its Q3 2026 earnings via an 8‑K filing, highlighting a net loss, cash position, and updates on its ovarian cancer drug program.

Company-level read

Ticker impact

$IMNNBearishHigh confidence
Context

Imunon filed an 8‑K reporting Q3 2026 net loss of $3.8 M and progress on its Phase 3 ovarian cancer trial IMNN‑001.

Expected impact

likely pressure as the market prices in the higher loss and cash concerns despite trial progress

Evidence & confidence

The earnings miss and limited cash raise immediate sell pressure; however, the Phase 3 enrollment update could attract speculative interest.

Market effects

Biotech sector may see modest pullback as investors reassess cash‑burn in early‑stage oncology companies.

US biotech micro‑caps could face heightened volatility in after‑hours trading.

Limited; the news is specific to Imunon and does not affect broader markets.

Counterpoint

The Phase 3 trial progress could outweigh the near‑term loss, offering a buying opportunity on dip.

Key entities

  • Imunon Inc.

    US‑listed biotech developing IMNN‑001 for ovarian cancer.

  • VoxelDox

    Partner receiving ThermoDox rights and providing Imunon with equity and milestone payments.

Related articles

$IMNNMedAI 8/10

Imunon (IMNN) Q3 2026 Earnings Call Transcript

Imunon (IMNN) reported Q3 2026 progress, highlighting Phase III IMNN-001 study for ovarian cancer. The company saw strong enrollment, independent validation, and a partnership with the National Cancer Institute. IMNN-001 aims to address a disease with low survival rates and limited treatment advances. The company expects 50% enrollment by Q1 2028 and completion by Q1 2029, with interim analysis in Q1 2030.

$IMNNLow

Imunon 3Q 2026: EPS ($0.64) — 10-Q Summary

Imunon (IMNN) reported a wider net loss of $3.81M in Q3 2026, though diluted EPS improved to ($0.64) from ($1.16) YoY. Operating expenses decreased 1%, with R&D costs down 6%. The OVATION 3 trial enrollment exceeded expectations, and the company advanced its NCI collaboration and MRD study. Imunon discontinued PLACCINE and IMNN-101 development in Q1 2026.

$IMNNHighAI 8/10

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollm

$IMNNHighAI 8/10

IMUNON presents translational data from ovarian cancer trial

IMUNON Inc. (IMNN) presented data from its Phase 2 OVATION 2 study of IMNN-001 in advanced ovarian cancer, showing improved survival and immune response. The trial compared IMNN-001 with chemotherapy against chemotherapy alone. The company is now conducting a Phase 3 trial, OVATION 3, to confirm these results. IMNN-001 is a DNA-based immunotherapy targeting IL-12 delivery to tumor tissue.

$IMNNMed

In an ovarian cancer trial, median survival was 14.7 months longer with added treatment

IMUNON, Inc. (Nasdaq: IMNN) announced new data from its Phase 2 OVATION 2 study, showing that IMNN-001 increased anti-tumoral T-cell activity in ovarian cancer patients. The treatment improved median overall survival by 14.7 months compared to standard care. The findings support the ongoing Phase 3 OVATION 3 trial. The data was presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting.

$IMNNMedAI 8/10

Imunon (IMNN) Q2 2026 Earnings Call Transcript

Imunon (IMNN) held its Q2 2026 earnings call. Management reported Phase 2 OVATION II median overall survival of 45.1 months vs 30.4 months, and PARP maintenance survival of 65.6 vs 41.4 months. Q2 R&D was $1.5M, G&A $1.3M, net loss $2.8M. Cash was $6.9M after a $10M financing.